Register
Login:
Share:
Email Facebook Twitter

Member Info for bigbob0228


Member Since: Mon, 7th Apr 2008

Number of Share Chat Posts (all time): 80
Number of Share Chat Posts (last 30 days): 1

Last Posted: 4 Sep '14


Post Distribution over the last 30 days




5 Jul '10


GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS



Porton Down, UK, 5 July 2010: GW Pharmaceuticals (AIM: GWP) hereby provides notification that the Company has today been notified of the following series of share transactions, the result of which is an increase in the beneficial interests of Dr Geoffrey Guy and Dr Stephen Wright.

The wife of Dr Stephen Wright, Research and Development Director, has today purchased 5,000 ordinary shares of 0.1p each at the market price of 110 pence per share. This purchase equates to 0.004% of the issued ordinary share capital.

Dr Geoffrey Guy, a Director and Executive Chairman of the Company, has today exercised an option to acquire 120,000 ordinary shares of 0.1p each, equating to 0.09% of the issued ordinary share capital at an exercise price of 36.2 pence per share. This follows the sale of 50,000 ordinary shares of 0.1p each on 30th June 2010, at the market price of 124 pence; 30,000 ordinary shares of 0.1p each on 2nd July 2010 at the market price of 109.6 pence and the sale of 38,678 ordinary shares of 0.1p each today at the market price of 109 pence per share. The total number of shares sold of 118,678 equates to 0.09% of the issued ordinary share capital.

Following these notifications Dr Guy's beneficial interest has increased to 18,345,274 ordinary shares, amounting to 14.11% of the shares in issue, and Dr Wright's beneficial interest has increased to 5,000 ordinary shares, amounting to 0.004% of the shares in issue.

The total number of shares outstanding in the Company is 130,041,372 ordinary shares of 0.1p each.



For further information, please contact:

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

Piper Jaffray Ltd (Nominated Adviser)

Neil Mackison/Rupert Winckler +44 (0) 203 142 8700
28 May '10


If they were to raise the bid up to 128 they might get a market going ??
30 Apr '10


Many thanks to fundymental from interactive invester for piece below.
30 Apr '10


Yes, we do have an upgrade. Rodman and Renshaw put out a piece on the 26th with a p tgt of 300p. First new piece I've seen for a while.

Boris Peaker, Ph.D., bpeaker@rodm.com

GW PHARMACEUTICALS (GWP.L: PRICE: £1.11; MARKET CAP: £143.48; Market Outperform) - EXTRACTING

SHAREHOLDER VALUE FROM THE CANNABIS PLANT

INITIATING COVERAGE

We are initiating coverage of GW Pharmaceuticals with a Market Outperform rating and a £3/share (300p) 12-month target price. We

believe that the company’s leading drug, Sativex, is safe and efficacious, and we anticipate formal approval in the UK and Spain in 2010.

NEAR-TERM REGULATORY APPROVAL

GW Pharmaceuticals (GW) is a leading pharmaceutical company focused on cannabinoid science, and the development of therapeutics

based on natural cannabinoid compounds. The company’s leading drug is Sativex, which is currently approved for cancer pain and

neuropathic pain in MS in Canada, and is under regulatory review for MS spasticity in the EU and Canada. We believe that the drug has

shown adequate safety and efficacy to justify approval.

ADDICTION CONCERNS ADDRESSED

GW successfully met the requirements of the addiction/drug likeness study requested by the FDA. The 30-subject trial used placebo and

active controls (dronabinol), and showed that Sativex does not appear to be addictive. Additionally, the cancer pain relief study showed

that the lowest dose of Sativex is more efficacious in pain relief than the higher doses, suggesting limited abuse potential in patients with

pain.

MS SPASTICITY AND CANCER PAIN PRESENT LARGE MARKETS

Due to the chronic unmet need in MS spasticity, and the need for new drugs to combat cancer pain, we believe that Sativex may find a

commercial opportunity in combination with existing drugs. Due to the novel mechanism of action and established safety, we don’t see a

direct competitor to Sativex in these markets. We estimate worldwide peak sales potential for Sativex of £350MM + in cancer pain and

£250MM+ in MS spasticity.

EXPERTISE IN CANNABINOID SCIENCE

Sativex is the company’s leading cannabinoid drug, in development for central nervous system indications. GW is a world leader in

cannabinoid science research, and the company’s pipeline includes novel cannabinoids for cancer, diabetes, epilepsy, and other

indications. We believe that the pipeline presents unrecognized upside to long-term oriented investors, while the launch of Sativex is a

potential proof of concept that may bring investor interest into the rest of GW’s pipeline.

VALUATION

GW partnered the commercial rights to Sativex with large companies around the world, and we estimate the company to collect sales

royalties of 30% in the UK, 25% in other European countries, and 20% in the US. GW does not plan to build a commercial organization,

and remains focused on drug discovery, which is largely paid by its partners. Although we anticipate earnings to be


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Share Price SpacerQPP1000593 
Share Price SpacerBigGib494 
Share Price Spacerdaveycaferacer481 
Share Price Spacerokenia459 
Share Price SpacerK3VMC380 
Share Price SpacerBrotherhumble368 
Share Price Spacermatlot343 
Share Price SpacerSpikeyj338 




Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.